Key result
Polymorphisms of the P2Y12 receptor gene, specifically SNP rs9859552, are associated with up to 20% less inhibition of platelet aggregation after in vitro blockade with cangrelor (p<0.05).
Why the study?
Does variation in the P2Y12 receptor gene affect in vitro platelet inhibition by cangrelor in healthy subjects?
Population
254 healthy subjects (platelet-rich plasma)
Comparison
In vitro addition of 0.05 and 0.25 microM… vs Baseline and comparison across different P2Y12…
Design
Preclinical
Loading...
Should not alter cangrelor use; hypothesis-generating for P2Y12 pharmacogenomics in humans.
Observational (n=254)
Does variation in the P2Y12 receptor gene affect in vitro platelet inhibition by cangrelor in healthy subjects?
Effect estimate: 20% less inhibition
p-value: p=<0.05
Polymorphisms in the P2Y12 receptor gene significantly contribute to interindividual variability in platelet inhibition by the direct P2Y12 antagonist cangrelor in vitro.
A 2009 study conducted an observational in Healthy subjects (n=254). P2Y12 receptor gene variation (e.g., SNP rs9859552) vs. Reference genotypes (e.g., CC homozygotes) was evaluated on Platelet aggregation after in vitro partial P2Y12 receptor blockade with cangrelor (20% less inhibition, p=<0.05). Polymorphisms of the P2Y12 receptor gene, specifically SNP rs9859552, are associated with up to 20% less inhibition of platelet aggregation after in vitro blockade with cangrelor (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: